Aruna Bio secures US patent for exosome-derived neuroinflammation treatment

A Georgia-based biotechnology company has secured a U.S. patent for an exosome-based therapy to treat neuroinflammation that occurs in a range of neurodegenerative disease, according to the manufacturer.

In a press release, Aruna Bio Inc. announced that AB126, a novel therapeutic derived from proprietary neural stem cells, can be utilized across multiple indications where neuroinflammation is the primary pathological driver, including conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, prion disease, motor neuron disease, spinocerebellar ataxia and spinal muscular atrophy.

Additional claims made within the patent also permit AB126 to be administered by multiple methods such as IV, intranasal, intrathecal, intraperitoneal, oral and direct delivery into the brain, per the release.

“We are excited to announce allowance of this method of use patent, as it validates the broad utility of our proprietary exosome platform for the treatment of neuroinflammatory conditions,” Steven Stice, PhD, co-founder and chief scientific officer of Aruna, said in the release. “As we continue to strengthen our robust patent portfolio, expanding its breadth of claims across indications and extending its protection, we are also preparing to advance in the clinic.”